Kornimate/medical-research-clean huggingface dataset:
effects of adapated physical activity program on kynurenin metabolism during refeeding in anorexia nervosa : apanor study

Conditions: Anorexia Nervosa

Summary: physical hyperactivity is often associated to anorexia nervosa (an). data suggest common central pathways between hyperactivity and anorexia. maintaining adapted physical activity (apa) during refeeding in an is controversial. many studies suggest beneficits of apa in an on body composition (increase fat free mass and better distribution of fat mass), mood regulation, bone metabolism. we recently reported benefits of maintaining physical activity during refeeding in a mice model of anorexia (activity-based anorexia model). these benefits involved the tryptophan-kynurenin pathway. thus, we aim in the apanor study to assess effects of apa during refeeding in an on kynurenin metabolism.


Eligibility criteria:
inclusion criteria: 1. female 2. patient \> 18 years 3. follow-up in the department of clinical nutrition of rouen 4. bmi ≥15,0 and \<18,5 kg/m² 5. diagnosis of anorexia nervosa according to dsm-v classification exclusion criteria: 1. physical activity contraindications : hemodynamic disorder, uncontrolled cardiovascular disease, intracranial hypertension 2. patients with poor understanding of spoken or written french 3. person deprived of their liberty by an administrative or judicial decision or person subject to a legal measure for the protection of adults 4. person subject to a safeguard of justice, guardianship or curatorship. 5. pregnant or breastfeeding woman
early intervention with therapeutic exercise in plantar fasciopathy

Conditions: Plantar Fascitis

Summary: the aim of this project is to evaluate the efficacy of a therapeutic exercise programme in patients with plantar fasciitis applied early and aimed at strengthening the hip and foot musculature.

all patients will be informed about the study to be carried out and will give their prior informed consent. the programme has a first part of teaching directed to patients by physiotherapists, and a second part of application at home, with a duration of 12 weeks. an experimental study will be designed with random assignment of patients with similar characteristics to two groups. the non-experimental group will receive their usual treatment (medication and recommnendations as stretching) and the experimental group will follow their usual treatment and also participate in the therapeutic programe.

Eligibility criteria:
inclusion criteria: * patients with referred pain in the medial plantar area of the heel, accentuated with initial steps after a period of inactivity but also worsening after prolonged body weight bearing, of at least 3 months evolution prior to inclusion in the study. * reproduction of the pain referred by the patient with palpation at the proximal insertion of the plantar fascia. exclusion criteria: * pregnancy. * injection of corticoids in the area in the 6 months prior to recruitment. * previous illnesses that may alter gait (central or peripheral neurological pathology, degenerative and inflammatory arthropathies, systemic illnesses). * existence of concomitant foot pathology (metatarsalgia, stress fractures, neuropathies due to entrapment, tendinitis, history of foot/ankle surgery, etc.). * people who do not have the capacity to understand and follow an exercise programme.

Keywords: therapeutic exercise strengthening
phase ii trial of bortezomib and doxorubicin in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer. the trial format is a single arm phase ii design wherein patients are treated with bortezomib iv on days 1, 4, 8, and 11 and with doxorubicin iv on days 1 and 8 of a 21-day cycle.


Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed metastatic breast cancer * measurable or evaluable disease * age \> 18, ps 0,1,2 * muga \> 45% * received one or fewer chemotherapies or investigational regimens for metastatic disease, no limit to the number of prior hormonal therapies. may have had single agent herceptin and/or herceptin plus single-agent chemotx. * must meet designated laboratory criteria within 14 days of enrollment exclusion criteria: * doxorubicin for metatstatic disease. * pregnant or lactating. * active infections, no myocardial infarction within 2 months of enrollment. * investigational drugs within 14 days of enrollment. * chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4 weeks of enrollment. * neuropathy that is \> grade 2. * active brain mets. * hypersensitivity to bortezomib, boron, or mannitol.
a study of camrelizumab combined with rivoceranib mesylate versus investigator's choice of regimen in treatment of patients with advanced hepatocellular carcinoma (hcc)

Conditions: Advanced Hepatocellular Carcinoma (HCC)

Summary: this is a randomized, open-label, international, multi-center, phase iii trial to evaluate the efficacy and safety of camrelizumab combined with rivoceranib mesylate versus investigator's choice of regimen in treatment of patients with hepatocellular carcinoma (hcc)


Eligibility criteria:
inclusion criteria: 1. subject must participate voluntarily and sign the informed consent form; 2. aged ≥ 18 years old, male or female; 3. histopathologically confirmed hepatocellular carcinoma; 4. has pd on treatment with prior anti-pd-1/pd-l1/ctla-4 monoclonal antibody (mab) administered either as monotherapy or as combination therapy. 5. no more than 2 lines of previous system treatment; 6. be able to provide fresh or archived tumor tissue samples; 7. patient with at least one measurable lesion (for stage i); 8. barcelona clinic liver cancer: stage b or c; 9. child-pugh score: ≤ 7; 10. ecog ps score of 0-1; 11. life expectancy of ≥ 12 weeks; 12. adequate organ function 13. must take one medically approved contraceptive measure exclusion criteria: 1. patients with any active, known or suspected autoimmune disorder; 2. patients who have used corticosteroids or other immunosuppressive agents for systemic treatment within 1 month prior to randomization; 3. with known severe allergic reactions to any other monoclonal antibodies; 4. received previous camrelizumab or rivoceranib mesylate treatment; 5. patients who discontinued icis treatment due to immune-related toxicity; 6. patients with known cns metastasis or hepatic encephalopathy; 7. patients with liver tumor burden greater than 50% of total liver in volume, or patients who have previously undergone liver transplantation;; 8. patients with symptomatic ascites or pleural effusion requiring paracentesis and drainage, or patients who have undergone ascites or pleural effusion drainage within 2 weeks before randomization; 9. patients with other malignancies currently or within the past 5 years; 10. patients with hypertension which cannot be well controlled by antihypertensives; history of hypertensive crisis or hypertensive encephalopathy; 11. uncontrolled cardiac diseases or symptoms； 12. known hereditary or acquired bleeding disorders; 13. clinically significant bleeding symptoms or clear bleeding tendency; 14. patients with gastrointestinal perforation or gastrointestinal fistula; 15. patients with significant vascular invasions with a high possibility of fatal bleeding; 16. patients with important arterial/venous thrombosis; 17. patients experiencing toxicity caused by previous anti-tumor therapy that has not recovered to grade ≤ 1; 18. patients with active infection; 19. patients with congenital or acquired immune deficiency; 20. patients who received live vaccines within 28 days prior to randomization, or are expect to be vaccinated during the treatment period; 21. patients with other potential factors that may affect the study results.
a brief intervention to reduce suicide risk in military service members and veterans - study 2 (safemil)

Conditions: Suicide; Suicide, Attempted

Summary: the investigators propose to test the efficacy of a brief, readily accessible, and personalized treatment called the safety planning for military (safe mil; stanley and brown, 2012).

background: mental health related hospitalizations and suicide are both significant public health problems within the united states department of defense (dod). there are limited evidence-based suicide prevention interventions that have been developed for military personnel and veterans who are experiencing suicide ideation or who have made a suicide attempt. objectives: to evaluate the efficacy of the safety planning for military (safe mil) on suicide ideation, suicide-related coping, and attitudes toward help seeking for hospitalized military personnel at high suicide risk. methodology: to test the efficacy of the adapted intervention, the investigators will randomize 186 patients to one of two conditions: safety planning for military (safe mil) or enhanced usual care (e-care). the safe mil condition (intervention) will consist of the safety planning intervention to help the suicidal individual with a collaboratively generated personal plan to mitigate or prevent a future suicidal crisis. the e-care will consist of the usual care patients receive at an inpatient facility during their hospitalization in addition to assessment services provided by independent evaluators who work directly with our research team. primary outcomes include suicide ideation, suicide-related coping, and attitudes toward help-seeking \[acceptability and initiation of services\]. patients in both conditions will be assessed on the dependent measures at the time of hospital admission (i.e., baseline), at the time discharge (follow-up interval 1 \[fu-1\]), at 1-month (follow-up interval 2 \[fu-2\]) and at 6-month (follow-up interval 3 \[fu-3\]).

Eligibility criteria:
inclusion criteria: * patient admitted due to recent suicide intent and/or suicide attempt within past month * baseline assessment completed within 48 hours of hospital admission * age of 18 years or older. exclusion criteria: * medical incapacity to participate and/or serious cognitive impairment * expected discharge within 72 hours of admission * expected deployment within 1-month * inability to read or understand english * inability to provide informed consent

Keywords: suicide prevention suicide attempt suicide ideation randomized controlled trial safety planning
telerehabilitation-based action observation treatment in children with hemiparetic cerebral palsy

Conditions: Hemiparetic Cerebral Palsy

Summary: the aim of this study is to evaluate the effectiveness of action observation therapy applied using two different telerehabilitation techniques (synchronous and asynchronous) to children with hemiparetic cerebral palsy.

action observation treatment (aot) is a new rehabilitation technique. aot involves the observation of purposeful actions, presented through a video-clip or performed by an operator, in order to imitate and then perform them. in this study, aot will be applied by observing actions to be presented via video-clips. 36 children with hemiparetic cerebral palsy who meet the inclusion criteria and agree to participate in the study will be included. the participants will be randomly divided into three groups. the groups are: a) the synchronous telerehabilitation group, where aot will be applied under the supervision of a physiotherapist via videoconferencing; b) the asynchronous telerehabilitation group, where aot will be applied under parental supervision; and c) control group. both the synchronous telerehabilitation group and the asynchronous telerehabilitation group will receive aot 5 days a week for 3 weeks, for a total of 15 sessions, in addition to conventional physiotherapy. the control group will only receive conventional physiotherapy. a total of three evaluations will be made at baseline (t0), at the end of treatment (t1), and at two months of follow-up (t2).

Eligibility criteria:
inclusion criteria: * presence of confirmed hemiparetic cerebral palsy * manual ability classification system ≤ 3 * age between 6 and 12 * absence of major visual and/or auditory deficits * sufficient cooperation to comprehend and complete the test procedure and participate in treatment * house functional classification score ≥4 * grade ≤2 on the modified ashworth scale exclusion criteria: * seizures uncontrolled by therapy * surgery and/or botulinum toxin-a injections in the upper limb within 6 months prior to the baseline assessment * having a disabling behavioral disorder to treatment

Keywords: cerebral palsy hemiparesis telerehabilitation action observation treatment
iressa in poor performance status patients with previously untreated advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: because of the demonstrated single agent activity and excellent tolerability in patients with refractory non-small cell lung cancer, zd1839 may be of benefit in the first-line treatment of patients with advanced non-small cell lung cancer who have poor performance status. in this phase ii trial, we will investigate the single agent activity of first-line zd1839 in patients with advanced non-small cell lung cancer with poor performance status

upon determination of eligibility, patients will be receive: * zd1839

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * biopsy proven non-small cell lung cancer * recurrent non-small cell lung cancer after previous surgery or radiation * advanced disease (stage iiib or iv) * no previous chemotherapy or biological therapy * require significant assistance with activities of daily living * measurable disease * adequate bone marrow, liver and kidney function * give written informed consent exclusion criteria: you cannot participate in this study if any of the following apply to you: * brain metastasis * meningeal metastasis * other uncontrolled malignancies * women pregnant or lactating * no measurable disease outside previous radiation therapy field please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Keywords: nsclc lung cancer non small cell lung cancer
correlation between circulating tumor cells and brain disease control after focal radiotherapy for metastases of breast cancer

Conditions: Brain Cancer; Breast Cancer

Summary: this study assesses the number of ctcs before and 4-5 weeks after focal stereotactic radiotherapy, in single or fractionated dose, and correlate with the local and distant brain progression-free survival in patients with metastatic breast cancer.

brain metastases (bm) are the most prevalent tumors of the central nervous system (cns), with a ratio of 10: 1 relative to primary tumors. in breast cancer, bm are becoming more frequent due to longer life expectancy. patients with her2-positive metastatic disease are prone to develop bm more often and they occur in 20 - 40% of cases. circulating tumor cells (ctc) originate from the primary tumor and can migrate to distant organs. the possible correlation between ctc and the incidence of brain metastases could help define radiotherapy in patients with oligometastatic or not so widespread disease in the brain. however, there are few studies that evaluate these scenarios. purpose: to assess the number of ctc before and 4-5 weeks after focal stereotactic radiotherapy in single (srs) or fractionated (sfrt) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer. potential invasion markers in these cells will be evaluated and correlated with clinical outcome. patients and methods: prospective, single-center research which will be developed at the radiation oncology department of ac camargo cancer center. patients with diagnosis of metastatic breast cancer to the brain with an indication of focal radiotherapy, srs or sfrt, will be recruited. the blood will be collected and processed for analysis of ctc by the iset method (rarecells, france). the invasion markers (her-2, cox-2, egfr, notch 1 and st6galnac5) will be analyzed on ctc by immunocytochemistry. expected results: if our hypothesis is proven, we may include the analysis and quantification of ctc in clinical practice as early indicator of local or distant recurrence in the brain.

Eligibility criteria:
inclusion criteria: * diagnosis of bm of breast cancer and indication of focal radiotherapy to the brain lesions. exclusion criteria: * patients who received wbrt less than 30 days from the initial ctc dosage. * patients who received systemic treatment for less than 7 days of the initial ctc dosage. * pregnant patients.

Keywords: circulating tumor cells stereotactic radiosurgery
what ssi duration is most effective? an online experiment with american adults

Conditions: Depression

Summary: in a previous study (https://osf.io/qdznc), the research team found that an 8-minute version of a single-session intervention for loneliness was more effective than a 23-minute version of it. the present work aims to further explore the relationship between intervention duration and effectiveness. in this online trial, participants will be randomized to a 15-minute single-session depression intervention called the action brings change (abc) program, a 10-minute version of it, a 6-minute version of it, or a 2-minute version of it. the main analysis will evaluate how change in depressive symptoms over eight weeks differs across conditions.


Eligibility criteria:
inclusion criteria: participants must be: * located in the united states * at least 18 years old * patient health questionnaire-8 (phq-8) score of at least 10 (moderate or more severe) at screener. * able to read and speak fluent english * able to access to the internet via a computer, tablet or smartphone for the next eight weeks exclusion criteria: * participants who have completed the first session of the study before or completed another study testing a depression intervention from our laboratory via the same participant recruitment platform in the past two months.

Keywords: single-session intervention length duration effectiveness active elements
effect of blood flow restriction training to muscle strength, dynamic stability, and acl injury prevention

Conditions: Healthy Subjects; Sports Level 1

Summary: the goal of this randomized clinical trial study is to compare low-load blood flow restriction (ll-bfrt), sham ll-bfrt, and high-load eccentric training (hl-et) in healthy level 1 sportsman. the main questions it aims to answer are: 1. does ll-bfr improve muscle strength better than sham ll-bfrt and hl-et? 2. does ll-bfr improve dynamic stability better than sham ll-bfrt and hl-et? 3. does ll-bfr prevent acl injury better than sham ll-bfrt and hl-et? participants will be randomized into three intervention groups: ll-bfrt, sham ll-bfrt, and hl-et. participants will be asked to do: * in ll-bfrt, participants will be asked to do ll eccentric training (including double leg squats, split squats, deadlifts, and monster walks) with a 30% of repetition maximum (rm) and 70% of arterial occlusion pressure (aop). * in sham ll-bfrt, participants will be asked to do ll eccentric training with a 30% of repetition maximum (rm) and 10% of arterial occlusion pressure (aop). * in hl-et, participants will be asked to do ll eccentric training with a 70% of repetition maximum (rm). researchers will compare ll-bfrt, sham ll-bfrt, and hl-et to see if muscle strength, dynamic stability, and acl injury prevention improve after the interventions and follow-up.

participants will be asked to do five sets of ten repetitions of each eccentric training, one-minute rest interval for each eccentric training and two mins rest interval between each set.

Eligibility criteria:
inclusion criteria: * being 15-35 years old * perform sports level 1 (soccer, basket ball, futsal, combat martial art) at least twice per week. * never had an history of acl injury * never had an history of sprain or strain grade iii * agree to participate until the end of this study period and sign the inform consent exclusion criteria: * having hypertension, blood circulation disease, anemia, obesity, diabetes, kidney failure, vena thromboembolic, cancer, and tumor. * disabilities or disabled people.

Keywords: blood flow restriction training sham blood flow restriction training bfr eccentric training
transcranial magnetic stimulation treatment for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: this study is investigating a new indication of transcranial magnetic stimulation (tms) by conducting a pilot randomized-controlled trial (rct) comparing structural neuronavigation-directed tms to sham-tms placebo therapy for treatment of generalized anxiety disorder (gad).

participants will complete structural mri for neuronavigation. participants will be randomly assigned to treatment condition. tms or sham-tms sessions will occur daily 5 days/week for 6 weeks. assessments will occur at pretreatment, weekly during treatment, post-treatment, and 3 month.

Eligibility criteria:
inclusion criteria: * diagnosed with gad as the principal or co-principal disorder * clinical global impression score ≥ 4 * hamilton anxiety rating scale ≥ 18 * hamilton rating scale for depression ≤ 17 * fluency in english * capacity to understand the nature of the study and willingness to sign informed consent form. exclusion criteria: * history of epilepsy or head trauma (loc \> 5 minutes) within the past 6 months. * lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery. * a review of patient medications by the study physician indicates an increased risk of seizure. * an active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency. * substance use disorder or ptsd within the past 6 months. * lifetime bipolar disorder, obsessive-compulsive disorder (ocd), psychotic disorder, mental retardation, or pervasive developmental disorder. * any psychotic features, including dementia or delirium. concurrent psychotherapy and unwillingness to discontinue * medication change within past 3 months. * current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months. * serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study. * any contraindication for participation in mri scan
clinical outcomes in candidemia patients based on in vitro susceptibility

Conditions: Blood Stream Infections; Candida

Summary: susceptibility testing is commonly employed in patients with bacterial infections in order to guide rational use of antibiotics; however, the use of antifungal susceptibility testing is limited due to lack of availability, costs, and delays in receiving results. the goals of antifungal susceptibility testing should mirror those of antibacterial susceptibility testing: to predict clinical response or failure. additionally, susceptibility reports should be used as a guide for physicians when transitioning patients from parenteral to oral antifungal agents. currently, it is unknown whether antifungal susceptibility testing impacts treatment decisions in hospitals that routinely perform candida susceptibility testing. the purpose of this study is to evaluate the changes in antifungal treatment based on in vitro susceptibility reports and how these decisions affect mortality, recurrence of infection, and length of hospital stay in candidemia patients.


Eligibility criteria:
inclusion criteria: * hospitalized patients with bloodstream infections due to candida species exclusion criteria: * patients will be excluded from this study if their medical charts contain incomplete outcome or susceptibility data. patients treated empirically or definitively with amphotericin-based products will also be excluded

Keywords: susceptibility testing